Publications of research supported by the Heffter Research Institute:

The following are published reports from projects that were supported in whole or in part by funds from the Heffter Research Institute :

Publications

(Click on a link to be taken to the abstract in the PubMed database)

 

  1. Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX. (2007) Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl). 2007 Sep 14; [Epub ahead of print]
  2. Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. (2007) Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 2007 Mar;39(1):13-9.
  3. Wittmann M, Carter O, Hasler F, Cahn R, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider F. (2007) Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharm 2007 Jan;21(1):50-64.
  4. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006 Nov;67(11):1735-40.
  5. Braden MR, Parrish JC, Naylor JC, Nichols DE. (2006) Molecular interaction of serotonin 5 HT2A receptor residues Phe339(6.51) and Phe340(6.52) with super-potent N-benzyl phenethylamine agonists. Mol Pharmacol 70:1956–1964.
  6. Parrish JC, Nichols DE. (2006) Serotonin 5-HT receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. J Neurochem 2006 Nov;99(4):1164-75.
  7. McLean TH, Chambers JJ, Parrish JC, Braden MR, Marona-Lewicka D, Kurrasch-Orbaugh D, Nichols DE. (2006) C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem. 49(14):4269-74.
  8. Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG. (2005) Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry 58:624–631.
  9. Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A Receptors. J Cognitive Neuroscience 17(10): 1497–1508.
  10. Carter OL, Presti DE, Callistemon C, Ungerer Y, Liu GB, Pettigrew JD. (2005) Meditation alters perceptual rivalry in Tibetan Buddhist monks. Curr Biol. 2005 Jun 7;15(11):R412-3.
  11. Gamma A, Brandeis D, Brandeis R, Vollenweider FX. (2005) The P3 in 'ecstasy' polydrug users during response inhibition and execution. J Psychopharmacol. 19(5):504-12.
  12. Vollenweider FX, Liechti ME, Paulus MP. (2005) MDMA affects both error-rate dependent and independent aspects of decision-making in a two-choice prediction task. J Psychopharmacol 19(4):366-374.
  13. Doering-Silveira E, Lopez E, Grob CS, Dobkin de Rios M, Alonso LK, Tacla C, Shirakawa I, Bertolucci PH, da Silveira DX. (2005) Ayahuasca in adolescence: a neuropsychological assessment. J Psychoactive Drugs 37(2): 123-128.
  14. da Silveira DX, Grob CS, Dobkin de Rios M, Lopez E, Alonso LK, Tacla C, Doering-Silveira E. (2005) Ayahuasca in adolescence: a preliminary psychiatric assessment. J Psychoactive Drugs 37(2): 129-133.
  15. Dobkin de Rios M, Grob CS, Lopez E, da Silveira DX, Alonso LK, Doering-Silveira E. (2005) Ayahuasca in adolescence: qualitative results. J Psychoactive Drugs 37(2): 135-139.
  16. Doering-Silveira E, Grob CS, Dobkin de Rios M, Lopez E, Alonso LK, Tacla C, da Silveira DX. (2005) Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J Psychoactive Drugs 37(2): 141-144.
  17. Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology. 2005 Jun;30(6):1154-62.
  18. Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX. (2004) Psilocybin impairs high-level but not low-level motion perception. Neuroreport Aug 26;15(12):1947-1951.
  19. Nichols CD, Sanders-Bush E. (2004) Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase-1, C/EBP-beta and ILAD-1, a novel gene with homology to arrestins. J. Neurochem. Aug;90(3):576-84.
  20. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172:145-156.
  21. Gamma A, Lehmann D, Frei E, Iwata K, Pascual-Marqui RD, Vollenweider FX. (2004) Comparison of Simultaneously Recorded [H2(15)O]-PET and LORETA During Cognitive and Pharmacological Activation. Human Brain Mapping 22:83-96.
  22. Nichols CD, Garcia EE and Sanders-Bush E (2003) Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration.nMolecular Brain Research 111:182–188.
  23. Umbricht D, Vollenweider FX, Schmid L, Grübel C, Skrabo A, Huber T and Koller R (2003) Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia Neuropsychopharmacology 28:170–181.
  24. Halpern JH and Pope HG (2003) Hallucinogen persisting perception disorder: what do we know after 50 years? Drug and Alcohol Dependence 69:109-119.
  25. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, and Nichols DE (2003) Serotonin 5-HT 2A receptor-coupled phospholipase C and phospholipase A 2signaling pathways have different receptor reserves. J. Pharmacol. Exp. Ther. 304:229-237.
  26. Chambers J and Nichols DE (2002) A homology-based model of the human 5-HT 2A receptor derived from an in silico activated G-protein coupled receptor. J. Computer-Aided Molecular Design 16:511-520.
  27. Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A (2002) Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Journal of Substance Abuse Treatment 23(4):273-283.
  28. Nichols, CD and Sanders-Bush, E. (2002) A single dose of lysergic acid diethylamide influences gene expression within the mammalian brain. Neuropsychoharmacology. Vol. 26/5 , pp. 634-642
  29. Whiteside MS, Kurrasch-Orbaugh D, Marona-Lewicka D, Nichols DE & Monte A. (2002) Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes. Bioorg Med Chem. 2002 Oct;10(10):3301-6.
  30. Nichols DE et al. (2002) Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide. J Med Chem. 2002 Sep 12;45(19):4344-9.
  31. Vollenweider FX (2002) Brain mechanisms of hallucinogens and entactogens. Dialogues in Clinical Neuroscience, Vol 3, No. 5, pp. 265-279.
  32. Vollenweider FX & Geyer MA (2001) A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Research Bulletin, Vol. 56, No. 5, pp. 495–507.
  33. Vollenweider, F. X., Geyer, M. A., and Greer, G. (2001) Acute psychological and neurophysiological effects of MDMA in humans. Heffter Review of Psychedelic Research 2:53-63.
  34. J.J. Chambers, D.M. Kurrasch-Orbaugh, M.A. Parker, and D.E. Nichols. (2001) "Enantioselective Synthesis and Pharmacological Evaluation of a Series of Super-Potent, Conformationally Restricted 5-HT2A/2C Receptor Agonists." J. Med. Chem., 44, 1003-1010.
  35. U. Laban, D. Kurrasch-Orbaugh, D. Marona-Lewicka, and D.E. Nichols. (2001) "A novel fluorinated tryptamine with highly potent and selective serotonin 5-HT1A receptor agonist properties," Bioorg. Med. Chem. Letters, 11, 793-795.
  36. Liechti ME, Gamma A, Vollenweider FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154:161–168.
  37. Liechti, M. E. and Vollenweider, F. X. (2001) Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Neuropsychobiology, Hum Psychopharmacol Clin Exp: 16:589-598.
  38. Liechti ME, Geyer MA, Hell D, Vollenweider FX (2001) Effects of MDMA (Ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 24(3):240-252.
  39. Gamma A, Liechti ME, Vollenweider FX (2001) Giving MDMA to Human Volunteers in Switzerland. In: Holland J (ed) Ecstasy: The complete guide. A comprehensive look at the risks and benefits of MDMA. Park Street Press, Rochester, pp 327-337.
  40. Halpern, JH, Pope, HG. (2001) Hallucinogens on the internet: a vast new source of underground drug information. Am J Psychiatry 158: 481-483.
  41. Frei E, Gamma A, Pascual-Marqui R, Lehmann D, Hell D, Vollenweider FX. (2001) Localization of MDMA-Induced Brain Activity in Healthy Volunteers Using Low Resolution Brain Electromagnetic Tomography (LORETA). Human Brain Mapping 14:152–165.
  42. Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, and Nichols DE. (2000) Effect of Ring Fluorination on thePharmacology of Hallucinogenic Tryptamines. J. Med. Chem., 43, 4701-4710.
  43. Buck A, Gucker PM, Schönbächler RD, Arigone M, Kneifel S, Vollenweider FX, Ametamey SM, Burger, C. (2000) Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods. Journal of Cerebral Blood Flow and Metabolism 20:253-262.
  44. Liechti ME, Baumann C, Gamma A, Vollenweider FX, (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22: 513-521.
  45. Liechti ME, Saur M, Gamma A, Hell D, Vollenweider FX (2000) Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23(4):396-405.
  46. Liechti ME and Vollenweider FX (2000) Acute psychological and physiological effects of MDMA (“Ecstasy“) after haloperidol pretreatment in normal healthy humans. European Neuropsychopharmacology 10:289-295.
  47. Liechti ME, Vollenweider FX (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers. J. Psychopharmacology 14(3):269-274.
  48. Gamma A, Buck A, Berthold T, Hell D, Vollenweider FX. (2000) 3,4-methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H215O]-pet in healthy humans. Neuropsychopharmacology 23(4):388-395.
  49. Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX. (2000) Mood state and brain electric activity in Ecstasy users. Neuroreport 11(1): 157-162.
  50. Callaway JC, McKenna DJ, Grob CS, Brito GS, Raymon LP, Poland RE, Andrade EN, Mash DC. (1999) Pharmacokinetics of Hoasca alkaloids in healthy humans. J Ethnopharmacology 65:243-256.
  51. Lebot V, Johnston E, Zheng QY, McKern D, McKenna DJ. (1999) Morphological, phytochemical, and genetic variation in Hawaiian cultivars of ‘Awa (kava, piper methysticum, piperaceae). Economic Botany 53(4): 407-418.
  52. Halpern, JH, Pope, HG. (1998) Do hallucinogens cause residual neuropsychological toxicity? Drug and Alcohol Dependence 53: 247-256.
  53. Vollenweider FX, Remensberger S, Hell D, Geyer MA. (1999) Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology 143:365-372.

Abstracts

 

  1. Nichols CD, Garcia EE, Sanders-Bush E. (2001) LSD and gene expression: a molecular genetic approach to understanding hallucinogenic drug action. Abstracts, Society for Neuroscience, Volume 26, 786.3.
  2. Liechti ME, Gamma A, Baumann C, Saur A, Hell D, Vollenweider FX (2001) Gender differences in the psychotropic effects of MDMA (“Ecstasy“). Biological Psychiatry (submitted).
  3. Liechti ME, Geyer MA, Hell D, Vollenweider FX (2000) MDMA („Ecstasy“) effects on sensorimotor gating after selective pretreatments in humans. Biological Psychiatry 47: 148S.
  4. Liechti ME, Gamma A, Hell D, Vollenweider FX (2000) Psychological Effects of MDMA („Ecstasy“) after Pretreatment with Selective Neuroreceptor Ligands in Healthy Volunteers. European Neuropsychopharmacology 10: 374.
  5. Cloak CC, Lutchmansingh P, Poland RE. (1999) Neurotoxic effects of MDMA as detected by 1H MRS. CPDD Abstracts for 1999 Annual Meeting.
  6. Liechti ME, Baumann C, Hell D, Vollenweider FX (1999) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. European Neuropsychopharmacology 9: S341.
  7. Nichols CD, Hazelwood LA, Blackshear MA, Sanders-Bush E. (1999) Lysergic acid diethylamide positively and negatively influences gene expression within the brain. Abstracts, Society for Neuroscience, Volume 25, 71.4.
  8. Roth BL, Kroeze WK, Willins DL, Savage JE. (1999) A conserved aspartic acid residue has an unexpected role in 5-HT2A receptor targeting. Abstracts, Society for Neuroscience, Volume 25, 484.9.
  9. Shapiro, DA, Kroeze WK, Kristiansen, K, Roth BL. (1999) Mutations in 5-HT2A receptor transmembrane region V decrease binding affinities to a variety of structurally diverse drugs. Abstracts, Society for Neuroscience, Volume 25, 484.10.
  10. Roth BL, Lopez E, Patel S, Kroeze WK. (1999) The multiplicity of Serotonin receptors: uselessly diverse molecules or an embarrassment of riches? The Neuroscientist, in press.
  11. Nichols CD, Blackshear MA, Sanders-Bush E. (1998) Characterization of lysergic acid diethylamide induced changes in gene expression. Abstracts, Society for Neuroscience, Volume 24, 692.6